Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors

被引：0

作者：

Subbiah, V. ^{[1
]}

Falchook, G. ^{[2
]}

Davis, A. A. ^{[3
]}

Wang, J. S. ^{[4
]}

de Miguel, M. ^{[5
]}

Santoro, A. ^{[6
]}

Maur, M. ^{[7
]}

Aljumaily, R. ^{[8
]}

Boni, V. ^{[9
]}

de Speville, B. Doger ^{[10
]}

Sun, Y. ^{[11
]}

Du, Y. ^{[12
]}

Lakshmikanthan, S. ^{[13
]}

Bedse, G. ^{[14
]}

Ward, A. ^{[15
]}

Zweidler-McKay, P. ^{[11
]}

Gandhi, L. ^{[16
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX USA

[2] HealthONE, Sarah Cannon Res Inst, Dept Drug Dev, Denver, CO USA

[3] Washington Univ St Louis, Div Oncol, St Louis, MO USA

[4] Florida Canc Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA

[5] START Madrid CIOCC HM Sanchinarro, Early Phase Clin Trial Program, Madrid, Spain

[6] Humanitas Univ, Dept Biomed Sci, Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Milan, Italy

[7] Azienda Osped Univ Policlin Modena, Div Oncol, Modena, Italy

[8] Univ Oklahoma, Sect Hematol Oncol, Stephenson Canc Ctr, Hlth Sci Ctr, Oklahoma City, OK USA

[9] NEXT Madrid Univ Hosp Quironsalud, Oncol Early Drug Dev Unit, Madrid, Spain

[10] START Madrid FJD Hosp Univ Fdn Jimenez Diaz, Early Phase Clin Trials Unit, Madrid, Spain

[11] ImmunoGen Inc, Clin Dev, Waltham, MA USA

[12] ImmunoGen Inc, Biostat, Waltham, MA USA

[13] ImmunoGen Inc, Translat Med, Waltham, MA USA

[14] ImmunoGen Inc, Clin Pharmacol, Waltham, MA USA

[15] MacroGenics Inc, Clin Dev, Rockville, MD USA

[16] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷

关键词：

D O I：

10.1016/j.ejca.2024.114703

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PB170

引用

页码：S72 / S73

页数：2

共 50 条

[41] First-in-human study of OBI-999: A globo H-targeting antibody-drug conjugate in patients with advanced solid tumors
Tsimberidou, Apostolia Maria
Hsu, Pei
Pearce, Tillman E.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors
Meng, Yanchun
Zhang, Jian
Zhao, Chuanhua
Cheng, Ying
Zhu, Liming
Song, Zhengbo
Xu, Nong
Wang, Zhen
Wang, Yanping
Du, Yiqun
Jing, Deqiang
Chen, Dinglu
Qu, Qiaofeng
Zhao, Xiwen
Li, Wei
Lu, Qiying
Tian, Wenzhi
Xu, Jianming
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
Infante, Jeffrey R.
Mendelson, David S.
Burris, Howard A., III
Bendell, Johanna C.
Tolcher, Anthony W.
Gordon, Michael S.
Gillenwater, Heidi H.
Arastu-Kapur, Shirin
Wong, Hansen L.
Papadopoulos, Kyriakos P.
INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 216 - 224
[44] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
Jeffrey R. Infante
David S. Mendelson
Howard A. Burris
Johanna C. Bendell
Anthony W. Tolcher
Michael S. Gordon
Heidi H. Gillenwater
Shirin Arastu-Kapur
Hansen L. Wong
Kyriakos P. Papadopoulos
Investigational New Drugs, 2016, 34 : 216 - 224
[45] First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors
Sommerhalder, David
Hamilton, Erika P.
Mukohara, Toru
Yonemori, Kan
Mita, Monica M.
Yamashita, Toshinari
Zheng, Jenny
Liu, Li
Maity, Arnab K.
Mishra, Natasha Homji
Bogg, Orlaith
Li, Meng
LoRusso, Patricia
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] Phase 1 Dose-Escalation Study of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor α-Targeting Antibody-Drug Conjugate, in Patients With Solid Tumors
Moore, Kathleen N.
Borghaei, Hossein
O'Malley, David M.
Jeong, Woondong
Seward, Shelly M.
Bauer, Todd M.
Perez, Raymond P.
Matulonis, Ursula A.
Running, Kelli L.
Zhang, Xiaoyan
Ponte, Jose F.
Ruiz-Soto, Rodrigo
Birrer, Michael J.
CANCER, 2017, 123 (16) : 3080 - 3087
[47] Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
Fedyanin, Mikhail
Tryakin, Alexey
Lisyanskaya, Alla Sergeevna
Solovyeva, Ekaterina
Fadeeva, Natalia
Gladkov, Oleg
Moiseyenko, Vladimir
Cheporov, Sergey, V
Shpigotskaya, Polina
Purmal, Andrei
Miller, Langdon L.
Leonov, Andrey
Zakurdaeva, Kristina
Gurova, Katerina
Gudkov, Andrei
Tjulandin, Sergei
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[48] First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy
Yu, Xianjun
Zhang, Jian
Sun, Yuping
Deng, Yanhong
Guo, Shuangshuang
Hong, Wei
Shi, Si
Liu, Rujiao
Gao, Shuiping
Dang, Qi
Zhang, Jianwei
Su, Weiguo
Shi, Michael
Fan, Songhua
Zhang, Bo
Pan, Beiqing
Jia, Xiaoyun
Wang, Jian
Zhong, Chen
Ma, Luguang
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[49] First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors
Shimizu, Toshio
Powderly, John
Abdul Razak, Albiruni
Lorusso, Patricia
Miller, Kathy D.
Kao, Steven
Kongpachith, Sarah
Tribouley, Catherine
Graham, Michelle
Stoll, Brian
Patel, Maulik
Sahtout, Mohammad
Blaney, Martha
Leibman, Rachel
Golan, Talia
Tolcher, Anthony
FRONTIERS IN ONCOLOGY, 2024, 14
[50] A Phase 1 dose escalation, safety, and pharmacokinetic study of PF-06650808, an anti-Notch3 antibody drug conjugate, in adult patients with advanced solid tumors
Rosen, L. S.
Wesolowski, R.
Gibson, B.
Baffa, R.
Liao, K. H.
Masters, J.
Hua, S. Y.
Deng, S.
Shazer, R.
Tolcher, A. W.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S725 - S725

← 1 2 3 4 5 →